The effectiveness of daily humanistic care in pharmaceutical care of patients with type 2 diabetes

Han, Xue; Zhou, Ya‐Qun; Shengxiong, Xie; Qingfa, Zeng; Guan, Yingjun

doi:10.1097/md.0000000000030136

Cited by 2 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, with the expansion of pharmacists in health teams around the world, important contributions to individuals with diabetes mellitus (DM) have been shown (Hui et al, 2022;Khan et al, 2022), especially in relation to glycemic control and reduction in the progression of disease complications (Aquino et al, 2019;Jeong, Lee, Ji, 2018;Rivera et al, 2021). The care provided by these professionals to the patient and to society is consolidated in the provision of pharmaceutical services, such as pharmacotherapeutic follow-up (PF).…”

Section: Introductionmentioning

confidence: 99%

Pharmacotherapeutic follow-up in patients with type 1 diabetes in context of judicialization: possibility optimize costs

Oliveira,

Cazarim,

Mendonça

et al. 2023

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

In Brazil, insulin analogs stand out as one of the most demanded medications by judicial means. However, the guarantee of judicial access does not guarantee rational use. In context, pharmacotherapeutic follow-up (PF) is shown to be clinical effective strategy for patients with diabetes. To evaluate direct medical costs one year after performing PF in patients with type 1 diabetes mellitus using insulin analogs ordered by court in Public Health System (Sistema Único de Saúde -SUS). This is a partial economic analysis, nested within a quasi-experimental study. Patients with T1DM who receive insulin analogs by judicialization in a medium-sized Brazilian city participated. The PF was conducted following the method adapted from the Pharmacotherapy workup (PW). Data were collected considering the period of one year before the start of the intervention and one year after the start of the intervention. Direct medical costs were evaluated and the difference in costs was calculated. 28 patients participated in the intervention. After PF, direct costs were -$3,696.78. Sensitivity analysis showed that there is a 33.4 % chance for PF to present cost savings when compared to baseline. The PF has the potential to reduce direct medical costs from the perspective of the SUS.

show abstract

Section: Introductionmentioning

confidence: 99%

Pharmacotherapeutic follow-up in patients with type 1 diabetes in context of judicialization: possibility optimize costs

Oliveira,

Cazarim,

Mendonça

et al. 2023

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

“…The article, “The effectiveness of daily humanistic care in pharmaceutical care of patients with type 2 diabetes”, [ 1 ] which published in Volume 101, Issue 41 of Medicine is being retracted due to an ongoing authorship dispute.…”

mentioning

confidence: 99%